Clinical Trial Update: Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial comparing two doses of pembrolizumab vs docetaxel in previously treated non-small cell lung cancer; study completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non Small Cell Lung Cancer (NSCLC) | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2017-01-18